This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in the management of bone and soft-tissue metastases
- 11C-Methionine vs. 18F-FDG PET in Soft Tissue Sarcoma Patients Treated with Neoadjuvant Therapy: Preliminary Results
- Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine
- PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
- Imaging of Bone Sarcomas
- 18F-FDG Kinetics and Gene Expression in Giant Cell Tumors
- PET Imaging of Osteosarcoma
- 18F-FDG PET for the Diagnosis and Grading of Soft-Tissue Sarcoma: A Meta-Analysis
- The Role of Quantitative 18F-FDG PET Studies for the Differentiation of Malignant and Benign Bone Lesions
- Dynamic PET 18F-FDG Studies in Patients with Primary and Recurrent Soft-Tissue Sarcomas: Impact on Diagnosis and Correlation with Grading
- Influence of Thyroid-Stimulating Hormone Levels on Uptake of FDG in Recurrent and Metastatic Differentiated Thyroid Carcinoma
- Grading of Tumors and Tumorlike Lesions of Bone: Evaluation by FDG PET
- Is There a Role for FDG PET in the Diagnosis of Musculoskeletal Neoplasms?
- (F-18) Fluorodeoxyglucose Positron Emission Tomography as a Predictor of Pathologic Grade and Other Prognostic Variables in Bone and Soft Tissue Sarcoma
- Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1